Program
brincidofovir
Also written as “Brincidofovir”, “CMX001” and “SyB V-1901”.
Its studies are mostly in Adenoviridae Infections · Cytomegalovirus Infections · Lymphoma, T-Cell · Smallpox · Kidney Diseases, led by 3 companies.
Drug pageBrincidofovir: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticalsits history only | 140 open or running | phase 3since Jun 11, 2010 | Oct 23, 2008 | none ahead |
| SymBio Pharmaceuticalsits history only | 41 open or running | phase 3since Jan 20, 2026 | Aug 29, 2020 | Jan 31, 2028phase 3 · NCT07387367 |
| Emergent BioSolutions | 10 open or running | phase 1since Jun 5, 2023 | Jun 5, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Emergent BioSolutions only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 5, 2023First study: phase 1 study in SmallpoxFirst studyNCT05935917 · 44 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA polymerase inhibitor”ChEMBL 37, by rule
Studies
The one study Emergent BioSolutions leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05935917Smallpox · United States | 1 | Completed | Aug 14, 2023 | 44 |
How it is read
Names in the registry
- “Brincidofovir”, 15 entries
- “CMX001”, 3 entries
- “SyB V-1901”, 1 entry
Conditions, from the studies’ own filings
- Adenoviridae Infections, 5 studies
- Cytomegalovirus Infections, 3 studies
- Lymphoma, T-Cell, 1 study
- Smallpox, 1 study
- Kidney Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.